

Acts on the central nervous system (the brain) and the endocannabinoid system



What is MENTANINE®?

It is a pure plant-based pharmaceuticalgrade cannabidiol derived from hemp



Natural omega-3 active IP formula

It effectively crosses the blood-brain barrier "BBB" to target neurological conditions such as:

ANXIETY

PTSD

DEPRESSION

ADDICTION



How does MENTANINE® work?

New Pathway Discovery:

The molecules bond and synergistically attach to the PPAR receptors allowing the formula to act on inflammation - causing mental conditions of the central nervous system (the brain) with amplified effects and efficacy. <u>Cannabidiol by itself did not do this in the pre-clinical trials</u>.

Science-based:

Mentanine® was developed in cooperation with **Dr. Steven Laviolette**, a neuroscientist, and his research team by deriving scientific data from 5 years of research and pre-clinical trials at his Western University laboratory. https://www.laviolettelab.com/



Dr. Laviolette


"Our cannabidiol-based formulation works synergistically and has multiple times the efficacy compared to other approved cannabidiol products on the market. This discovery sets the stage for substantially smaller dosages of cannabidiol generating the desired results without the negative side effects."



One Mentanine® capsule contains 21.5 mg of water-soluble cannabidiol + IP formula. The synergistic effect resulting from cannabidiol + <u>omega-3 active ingredients</u>, is multiple times more effective than pure water-soluble cannabidiol.

The delivery method for maximum absorption

- As a <u>water-soluble and bioavailable powder formula</u>, Mentanine[®], facilitates a very efficient and safe oral delivery method.
- Mentanine® capsules are <u>specially coated to ensure a targeted delivery system</u>. This coating facilitates higher absorption and provides a barrier that prevents formula dissolution or disintegration in a gastric environment. Mentanine® bypasses the stomach, enhances absorption, and minimizes potential liver toxicity.
- Mentanine® can be administrated with a significantly faster rate of absorption and significantly smaller doses compared to other cannabidiol medications, therefore, reducing the negative side effects of liver toxicity caused by the high consumption of cannabidiol products available today.



Small Dosage

Mentanine® may be administered orally as either a capsule or dissolved in an oil solution. Users may also take liquid formula sublingually (under the tongue) or through intranasal (through the nose) routes.

The Advantage

The advantage of Mentanine® is its effectiveness and efficacy, - only a small oral dose of 30mg to 60mg of cannabidiol daily is recommended by our scientists, as compared to a wide range of oral doses from 100mg/day to 800mg/day.

To ensure safety and effectiveness, we advise first-time users to **consult their physicians before taking Mentanine®**, especially those taking antidepression medication. The list of cannabidiol "CBD" and antidepressant interactions causing adverse reactions can be found at www.canaqueststore.com

Mental Health Conditions

Mentanine® is highly bioavailable and is a fast-acting formula that can interact within the Central Nervous System (CNS), the brain. This phenomenon facilitates Mentanine® to act on brain inflammation that contributes to neurological conditions such as Anxiety, Depression, and PTSD.

info@canaqueststore.com Certificate of Analysis (COA) and more information visit www.canaqueststore.com



CanaQuest has been named: 2022's Global Excellence Awards: **Best Medical Cannabis and Botanical Oils Product Development Company, 2022 – North America**...by Global Health & Pharma, UK

About CanaQuest: An award-winning, life-sciences company, focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The Company is involved in R&D of medical formulations and delivery systems to be used in human trials in order to apply for a Drug Identification Number (DIN) from the US-FDA. CanaQuest is the industry partner for research and product development with Dr. Steven Laviolette, a professor, and neuroscientist, at Western University, London, Ontario. Dr. Laviolette is a scientific veteran with decades of research experience in the field of mental health and cannabinoids and he oversees a dedicated team of 13 scientists.